Prostate Cell News Volume 9.49 | Dec 21 2018

TOP STORY

Single-Cell Analysis Identifies LY6D as a Marker Linking Castration-Resistant Prostate Luminal Cells to Prostate Progenitors and Cancer

Researchers revealed that LY6D⁺ castrate-resistant luminal cells could produce LY6D⁻ luminal cells. In contrast, in luminal cells lacking PTEN, LY6D⁺ cells predominantly gave rise to LY6D⁺ tumor cells, contributing to high-grade PIN lesions. [Cell Rep] Full Article | Graphical Abstract

(Ranked by impact factor of the journal)

Nuclear MET Requires ARF and Is Inhibited by Carbon Nanodots through Binding to Phospho-Tyrosine in Prostate Cancer

Aberrant MET/nMET elevation correlated with ARF in human prostate cancer specimens. Mechanistically, ARF elevated nMET through binding to MET cytoplasmic domain to stabilize MET. Furthermore, carbon nanodots resensitized cancer cells to MET inhibitors through DNA damage response. [Oncogene] Abstract

Modulating the Cellular Uptake of Fluorescently Tagged Substrates of Prostate-Specific Antigen before and after Enzymatic Activation

The addition of a tetra-glutamic acid group to the N-terminus of the intact sequence was shown to reduce cellular uptake of the intact substrate prior to activation by prostate-specific antigen (PSA). In contrast, masking the C-terminal carboxylic acid group of the substrate as a methyl ester was shown to improve cellular uptake of the peptide fragment after activation by PSA. [Bioconjug Chem] Abstract

Human Ex Vivo 3D Bone Model Recapitulates Osteocyte Response to Metastatic Prostate Cancer

Scientists integrated an engineered bone tissue model formed by 3D-networked primary human osteocytes, with conditionally reprogrammed (CR) primary human prostate cancer (PCa) cells. CR PCa cells induced a significant increase in the expression of fibroblast growth factor 23 by osteocytes. [Sci Rep] Full Article

Long Noncoding RNA PCA3 Regulates Prostate Cancer through Sponging miR-218-5p and Modulating High Mobility Group Box 1

Prostate cancer antigen 3 (PCA3) knockdown or miR-218-5p overexpression suppressed prostate cancer (PCa) cell proliferation, migration, and invasion, but promoted apoptosis. PCA3 weakened cell viability and mobility whereas induced apoptosis through binding with miR-218-5p. Meanwhile, miR-218-5p also inhibited PCa tumorigenesis via downregulation of high mobility group box 1. [J Cell Physiol] Abstract

HOXB13 Interaction with MEIS1 Modifies Proliferation and Gene Expression in Prostate Cancer

Researchers sought to interrogate the biochemical and functional interactions between HOXB13 and MEIS in prostatic cells with a goal of defining how the HOXB13-MEIS complex impacts prostate cancer pathobiology and define the extent to which the oncogenic activity of p.Gly84Glu germline mutation is related to its effect on HOXB13-MEIS interaction/function. [Prostate] Abstract

Coffee Diterpenes Kahweol Acetate and Cafestol Synergistically Inhibit the Proliferation and Migration of Prostate Cancer Cells

The anti-proliferation and anti-migration effects of six potentially active types of coffee compounds, including kahweol acetate, cafestol, caffeine, caffeic acid, chlorogenic acid, and trigonelline hydrochloride, were evaluated using LNCaP, LNCaP-SF, PC-3, and DU145 human prostate cancer cells. [Prostate] Abstract

MicroRNA-150 Suppresses Epithelial Mesenchymal Transition, Invasion and Metastasis in Prostate Cancer through the TRPM4-Mediated β-Catenin Signaling Pathway

The upregulation of miR-150 or knockdown of targeting transient receptor potential melastatin 4 (TRPM4) was observed to suppress epithelial-mesenchymal transition, proliferation, migration and invasion in vitro in addition to restrained tumor growth and metastasis in vivo. [Am J Physiol Cell Physiol] Abstract

GRP78 Modulates Cell Adhesion Markers in Prostate Cancer and Multiple Myeloma Cell Lines

In PC3 cells, glucose regulated protein 78 (GRP78) knockdown (KD) significantly decreased E-cadherin (cad) expression likely associated with the induction in TGF-β1 expression. Furthermore, GRP78 KD also triggered drastic changes in PC3 cell morphology and decreased their adhesion to osteoblasts dependent, in part, to the reduced N-cad expression. [BMC Cancer] Full Article

Expression of FGD4 Positively Correlates with the Aggressive Phenotype of Prostate Cancer

Inhibition of frabin (FGD4) resulted in reduced cell migration and CDC42 activities in PC-3 cells whereas, ectopic expression of FGD4 induced cell migration, altered expression of mesenchymal and epithelial markers and activation of CDC42/PAK signaling pathway. [BMC Cancer] Full Article

Subscribe to one of our other 19 science newsletters such as Mammary Cell News & ESC & iPSC News.

LncRNAs in Cancer: Another Layer of Complexity

The authors aim to review the most well characterized lncRNAs with important roles in hallmarks of cancer, additionally including lncRNAs with higher potential for clinical application. [J Gene Med] Abstract

Visit our reviews page to see a complete list of reviews in the prostate cell research field.

Astellas and Pfizer Announce Positive Top-Line Results from Phase III ARCHES Trial of XTANDI^® (Enzalutamide) in Men with Metastatic Hormone-Sensitive Prostate Cancer

Astellas Pharma Inc. and Pfizer Inc. announced that the Phase III ARCHES trial evaluating XTANDI^® plus androgen deprivation therapy (ADT) in men with metastatic hormone-sensitive prostate cancer met its primary endpoint, significantly improving radiographic progression-free survival versus ADT alone. [Astellas Pharma Inc.] Press Release

Sophiris Bio Provides Updates on Phase IIb Localized Prostate Cancer Trial

Sophiris Bio Inc. provided an update from its Phase IIb study of topsalysin for localized prostate cancer, including top-line safety and biopsy results from the patients who received a second administration of study drug, which appeared to be safe and generally well-tolerated. [Sophiris Bio Inc.] Press Release

Top Cancer Doctor Resigns as Editor of Medical Journal

Dr. José Baselga, the former chief medical officer of Memorial Sloan Kettering Cancer Center, resigned under pressure as one of the editors-in-chief of Cancer Discovery, a prominent scientific journal, after he failed to accurately disclose his conflicts of interest in dozens of articles in medical journals. [The New York Times] Editorial

National Academy President Breaks Her Silence on Ejecting Sexual Harassers

It has been seven months since the presidents of the U.S. National Academies of Sciences, Engineering, and Medicine in Washington, D.C., announced they had “begun a dialogue” about the standards of professional conduct required for membership in their exclusive ranks. [ScienceInsider] Editorial

Max Planck Society Ends Elsevier Subscription

The Max Planck Society, an enormous German research organization 14,000 scientists strong and comprising multiple research institutes, has ended its subscription to Elsevier journals, the organization announced in a statement. [The Scientist] Editorial

NEW AACR Annual Meeting 2019
March 29-April 3, 2019
Atlanta, Georgia, United States

Visit our events page to see a complete list of events in the community.

NEW Postdoctoral Scientist – Prostate Oncobiology (Cancer Research Manchester Institute)

NEW Faculty Position – Radiation Oncology & Molecular Radiation Sciences (Johns Hopkins University)

NEW Research Fellow – Prostate Cancer Pathology (Weill Cornell Medicine)

Tenure-Track/Tenured Faculty Positions – Cancer Biology (University of Chicago)

Assistant Professor – Department of Integrative Biology & Pharmacology (University of Texas Health Science Center at Houston)

Faculty & Leadership Positions- Cancer-Focused Target & Drug Discovery (The University of New Mexico)

Postdoctoral Associate – Molecular and Cell Biology (Baylor College of Medicine)

Postdoctoral Fellow – Advanced Prostate Cancer Research (Cleveland Clinic)

Postdoctoral Fellow – Cancer Immunotherapy (University of Notre Dame)

Research Fellow – Prostate Cancer (Sechenov University)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here.